- Home
- AQST vs RCS Comparison
AQST vs RCS Comparison
Compare AQST & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- RCS
- Stock Information
- Founded
- AQST 2004
- RCS 1994
- Country
- AQST United States
- RCS United States
- Employees
- AQST N/A
- RCS N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- AQST Health Care
- RCS Finance
- Exchange
- AQST Nasdaq
- RCS Nasdaq
- Market Cap
- AQST 390.4M
- RCS 354.7M
- IPO Year
- AQST 2018
- RCS N/A
- Fundamental
- Price
- AQST $5.84
- RCS $7.83
- Analyst Decision
- AQST Strong Buy
- RCS
- Analyst Count
- AQST 7
- RCS 0
- Target Price
- AQST $10.29
- RCS N/A
- AVG Volume (30 Days)
- AQST 3.6M
- RCS 141.1K
- Earning Date
- AQST 11-03-2025
- RCS 01-01-0001
- Dividend Yield
- AQST N/A
- RCS 10.12%
- EPS Growth
- AQST N/A
- RCS N/A
- EPS
- AQST N/A
- RCS N/A
- Revenue
- AQST $44,132,000.00
- RCS N/A
- Revenue This Year
- AQST N/A
- RCS N/A
- Revenue Next Year
- AQST $51.50
- RCS N/A
- P/E Ratio
- AQST N/A
- RCS N/A
- Revenue Growth
- AQST N/A
- RCS N/A
- 52 Week Low
- AQST $2.12
- RCS $4.51
- 52 Week High
- AQST $6.43
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- AQST 62.29
- RCS 69.82
- Support Level
- AQST $5.47
- RCS $7.58
- Resistance Level
- AQST $5.93
- RCS $8.00
- Average True Range (ATR)
- AQST 0.36
- RCS 0.13
- MACD
- AQST 0.01
- RCS 0.03
- Stochastic Oscillator
- AQST 62.43
- RCS 74.25
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.